Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Recent advances of traditional Chinese medicine on the prevention and treatment of COVID-19

DAI Yu-Jie¹, WAN Shi-Yao¹, GONG Shuai-Shuai, LIU Jin-Cheng, LI Fang*, KOU Jun-Ping*

Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, Nanjing 211198, China

Available online 20 Dec., 2020

[ABSTRACT] Coronavirus disease-2019 (COVID-19) is a new highly infectious disease caused by a novel coronavirus. Recently, the number of new cases infected pneumonia in the world continues to increase, which has aroused great concern from the international community. At present, there are no small-molecule specific anti-viral drugs for the treatment. The high mortality rate seriously threatens human health. Traditional Chinese medicine (TCM) is a unique health resource in China. The combination of TCM and Western medicine has played a positive and important role in combating COVID-19 in China. In this review, through literature mining and analysis, it was found that TCM has the potential to prevent and treat the COVID-19. Then, the network pharmacological studies demonstrated that TCM played roles of anti-virus, anti-inflammation and immunoregulation in the management of COVID-19 via multiple components acting on multiple targets and multiple pathways. Finally, clinical researches also confirmed the beneficial effects of TCM on the treatment of patients. This review may provide meaningful and useful information on further drug development of COVID-19 and other viral infectious diseases.

[KEY WORDS] Novel coronavirus pneumonia; Prescription of traditional Chinese medicine; Single Chinese herb; Active ingredients of traditional Chinese medicine; Viral infection

[Introduction] Since December 2019, a novel coronavirus (named “severe acute respiratory syndrome coronavirus 2”, SARS-CoV-2) has erupted around the world. On March 12, 2020, the World Health Organization has officially declared coronavirus disease 2019 (COVID-19) as a global pandemic. According to the epidemic real-time data statistics, as of July 12, a total of 85 522 people have been diagnosed in China, with 4 648 deaths, and 12 756 366 people have been diagnosed abroad, with 562 975 deaths. The study found that the process of infection caused by SARS-CoV-2 is closely related to angiotensin-converting enzyme 2 (ACE2). The spike protein (S protein) of SARS-CoV-2 enters human cells through binding ACE2 receptor and then drives the virus to reproduce and attack new cells [1, 2]. The clinical symptoms of COVID-19 patients mainly include fever, cough, fatigue, myalgia, diarrhea and complications of multiple organ damage [3, 4]. Currently, specific small-molecule anti-viral drugs have not been available for the treatment. The COVID-19 is still a serious threat to human health, and effective prevention and treatment are crucial in this situation.

COVID-19 has been considered to belong to the category of “epidemic disease” in traditional Chinese medicine. The cause is that the human body feels the external toxin and pathogen. The pathogenesis is mainly “wet, heat, poison, stasis, deficiency” and the lesions are mainly in the spleen, lungs and stomach [5, 6]. Chinese herbalists have accumulated valuable experience and played an essential role in the fight against the disease for thousands of years [7]. The General Office of the National Health and Health Commission of China and the Office of the State Administration of Traditional Chinese medicine (TCM) issued “Diagnosis and Treatment of Pneumonia Caused by Novel Coronavirus Infection”, which reflects the characteristics and advantages of TCM in the prevention and treatment of pneumonia [8, 9]. Early intervention of TCM has effectively alleviated the development of the disease. The combination of TCM and Western medicine reduced adverse events and other complications induced by glucocorticoid, anti-biotic and anti-viral treatments [10].

At present, the published reviews on the research progress of TCM in the prevention and treatment of COVID-19 mainly focus on the following aspects: summarize the under-
standing of the etiology, pathogenesis and syndrome characteristics of COVID-19 by the theory of TCM [11], review the clinical application [12,13] or explore the rules of TCM [14] and new natural compounds with anti-SARS-CoV-2 activity [15]. Whereas, our present review mainly focuses on the usage of TCM prescriptions, its extracts and active ingredients through literature mining analysis, experimental research and clinical application analysis. What’s more, we summarized the names, compositions, specific action pathways and characteristics of TCM which have potential anti-SARS-CoV-2 activity in the form of tables and pictures. This study might provide some support or new clues for the prevention and treatment of COVID-19 and other viral infectious diseases.

**Literature analysis of the potential efficacy of the TCM for the prevention and treatment of COVID-19**

It is found that TCM has anti-virus, anti-inflammation, immunoregulation functions through literature mining and analysis. Hence, they are considered to have the potential to treat COVID-19. The Office of the State Administration of TCM has selected Qingfei Paidu Decoction (QFPD) as a general prescription for the prevention and treatment of COVID-19. This prescription is based on Mahuang Decoction (MHD), Xiaochaihu Tang (XCHT), Wuling Powder (WLP), Shengan Mahuang Decoction (SGMHD) and Ju-Zhi-Jiang Decoction (JZJD), and is suitable for patients with mild symptoms, critical and convalescent patients. QFPD could play a rapid antiviral effect and shorten the treatment time of patients through the TCM theoretical analysis combined with the initial clinical observations [16]. It was believed that Huashibaidu prescription (HSBD) could regulate the qi of the lung through the literature analysis. Hence, it was recommended for the treatment of severe pneumonia through multiple targets [17]. Symptoms of qi deficiency often appear in convalescent patients. Shengmai San (SMS) is a classic prescription that can be applied to the diseases of qi and yin-deficiency and also has pharmacological effects such as anti-fibrosis. What’s more, it could accelerate the recovery time of patients and prevent the occurrence of sequelae [18]. At the same time, literature demonstrated that the Yiqi Fumai Lyophilized Injection (YQFM) could treat COVID-19 with cardiovascular disease [19]. Additionally, Xuebijing injection (XBJ) contains Chinese herbal extracts of Carthamus tinctorial, Radix Paeniae Rubra, Liguisticum chuanxiong Hort, and Salvia. According to the current clinical basis of XBJ, it has in-depth research value in the treatment of severe pneumonia patients [20]. In the trial version seven, Huoxiang Zhengqi Powder (HXZQ), Jinhua Qinggan Granules (JHQG), Lianhua Qingwen Capsules (LHQW), Shufeng Jiedu Capsules (SFJD), Reduning Injection (RDN) and other Chinese patent medicines were also mentioned. HXZQ is a frequently-used damp-clearing prescription and has efficacy of reliving super-ficicies, dispersing dampness, and harmonizing stomach. Combined with HXZQ, it not only has anti-bacterial and anti-viral effects but also could regulate gastrointestinal function and the body’s immunity. It is considered that it has the potential to treat COVID-19 with the digestive tract as the first symptom [21]. At the same time, it is found that HXZQ, JHQG, LHQW and SFJD have a potential role to improve the symptoms of fever, fatigue and gastrointestinal discomfort in COVID-19 patients during medical observation period discovered by searching and analyzing Chinese and English databases [22]. Another report showed that the volatile oil of TCM has the functions of anti-tussive, expectorant, anti-viral and immune regulation. Chinese herbal medicines such as Agastache rugosa, tangerine peel, Atractylodis Rhizoma and Atractylodes macrocephala may be potentially beneficial for the treatment of COVID-19 [23]. Besides, compound glycyrrhizin has anti-viral, anti-inflammatory and hormone-like effects. Literature analysis found that it could reduce the incidence of a late hormone withdrawal syndrome in patients with COVID-19 [24]. Through the analysis of the above literature, the potential feasibility of the TCM prescriptions for the treatment of COVID-19 was elucidated. More experimental and clinical research are still needed to prove the safety and effectiveness of single Chinese herbs and natural active ingredients.

**Network pharmacological studies of the TCM for the prevention and treatment of COVID-19**

Amounts of network pharmacological studies have suggested that the possible mechanisms of TCM for the treatment of COVID-19 include anti-virus, anti-inflammation, immunoregulation, and others through multiple components acting on multiple targets and multiply pathways. The relevant studies were summarized as follows.

**Anti-virus pathways**

Existing researches showed that SARS-CoV-2 3CL hydrolase (Mpro) is vital for the replication of SARS-CoV-2 and plays an indispensable role in the proteolytic processing of viral polyproteins (essential proteins for viral replication and function) [25]. Therefore, TCM with the capacity to target Mpro or ACE2 holds the promise to prevent the infection of SARS-CoV-2. Through network pharmacology and molecular docking methods, Mpro and ACE2 were used as targets to determine the binding energy, and it was found that HXZQ [26], JHQG [27], LHQW [28] and XBJ [29] had a good binding force and exerted a therapeutic role by inhibiting virus entry and replication. Other literature indicated that the phosphatidylinositol-3 kinase (PI3K)/total protein kinase B (AKT) pathway could regulate various types of angiogenesis and cell proliferation, which was related to the replication, assembly and pathogenicity of SARS-CoV-2 [31]. Network pharmacological analysis indicated that HXZQ [32], Qingfeipaidu Decoction (QFPD) [33] and XBJ [28,34] could also play a therapeutic role by regulating PI3K-Akt to inhibit virus invasion and replication.

Moreover, some natural products such as baicalin, hes-
peridin, glycyrrhizin and nicotinamide could play an antiviral effect of COVID-19 through the ACE2 receptor [36].

**Anti-inflammation pathways**

The “cytokine storm” is one of the main pathogenic mechanisms of COVID-19 [36]. It means that the body will produce and release a variety of inflammatory factors after being infected, such as Tumor Necrosis Factor-α (TNF-α), Interleukin-1β (IL-1β), Interleukin-6 (IL-6), Interleukin-12 (IL-12) and Interferon-α (IFN-α), Interferon-β (IFN-β). The release of “inflammatory” cytokines will induce new cytokine production and release which will in turn cause cell and organ damage. Therefore, improving the body’s cytokine storm and oxidative stress status presumably could reduce the severity and mortality rate. HXZQ [37], JHQG, LHQW, QFPD, XBJ, Xiyanping Injection (XYP) [38], a TCM composition containing Agastache rugosa, Chrysanthemi Indici Flos, Moslae Herba, and Artemisia annua could act on TNF, MAPK, NF-κB such signal pathways to suppress the elevated cytokine levels. Additionally, vitamin C, curcumin and glycyrrhizin exerted a potential protective effect on SARS-CoV-2 infection by preventing cytokine storms [39]. It is worth noting that the arachidonic acid (AA) metabolic pathway can mediate the production of multiple inflammatory factors [40], such as monococyte chemoattractant protein-1 (MCP-1), TNF, IL and IFN etc. Therefore, it is considered to be closely related to the occurrence and development of inflammation. Cluster model analysis revealed that HXZQ, JHQG, LHQW, QFPD, XBJ, RDN and XYP have potential inhibitory effects on AA pathway to treat pneumonia caused by SARS-CoV-2 through alleviating “cytokine storm” [41].

**Immunoregulation pathways**

Virus-infected cells release signals to recruit and activate immune cells. These immune cells secrete a variety of cytokines and chemokines to recruit more immune cells to the lesion site. However, this can lead to excessive immune responses and damage the body. TCM could alleviate excessive immune responses to restore normal physiological functions of the body. Based on the network pharmacology, LHQW was reported to have 55 common targets with SARS-CoV-2 [42], which were enriched in immunity (mainly the innate immune pathway induced by Type I interferon) and inflammation (TNF, IL-17, Toll-like receptors) [28]. The significant pathways of TRQ included Th17 cell differentiation pathway, MAPK, EGFR and TNF signaling pathway, which could alleviate excessive immune response, inhibit activated cytokines and eliminate inflammation [39]. A TCM prescription containing Tripterygium Wilfordii could regulate immunity against viruses [50].

**Others**

To date, other potential targets and pathways of Chinese herbal medicine prescriptions were predicted through network pharmacological analysis. For example, the increase of creatine kinase (CK) and lactate dehydrogenase (LDH) is related to lung cell damage and systemic symptoms [38], thus, HXZQ [38] may treat COVID-19 by reducing CK and LDH levels to improve oxygenation index and systemic symptoms. The potential signal pathways of Shufeng Jiedu Capsule (SFJD) for preventing and treating COVID-19 were IL-17, HIF-1 and Toll-like receptors, and the targets were IL-10, IL-6, prostaglandin-endoperoxide synthase (PTGS), Glycogen synthase-3 (GSK3B), transcription activator-1 (STAT-1) [39, 56]. HSBD showed 49 potential targets for COVID-19 including IL-6, TNF, MAPK1, MAPK8 and IL-1β [53]. Shengmai injection (SMI) treated COVID-19 through caspase (CASP), PTGS, NOS and other signaling pathways [38], and YQFM played a role in the early therapy of COVID-19 by inhibiting microvessel exudation, invigorating qi, astringing and solidifying [39]; it was also helpful for acute and severe cardiopulmonary patients [19].

There is a myriad of literature on network pharmacology analysis of single Chinese herbs and natural products. For example, Agastache rugosa showed 16 active ingredients and 10 related targets, which were acted on Toll, MAPK and other signaling pathways [60]. Seven effective compounds, forty-nine corresponding targets and thirty-one pathways were screened from Rhubarb and illustrated that it could treat COVID-19 through multi-component and multi-target [61]. Moreover, Quercetin and (-)-Epigallocatechin gallate and other 12 TCM monomers showed similar affinity to IL-6, ACE2 and SARS-CoV-2 as recommended medicines, and thus played a vital role in the treatment of COVID-19 [62].

Additionally, there are still many TCM prescriptions in the experimental research stage. For example, A centralizing and lung-saving medicine composition might reverse the progression of COVID-19 and reduce the deterioration rate [63]. There are some TCM sachets [64], nebulizers [65], fumigation preparations [66] and aromatherapy [67] with disinfection function under research which could help stop the spread of the epidemic.

**Clinical study of the TCM for the prevention and treatment of COVID-19**

A randomized clinical trial on LHQW of 284 COVID-19 patients is useful to confirm the beneficial effect of TCM. In the trial, 142 patients were given LHQW for 14 consecutive days (4 capsules, three times a day), the results manifested that the recovery rate (91.5% vs 82.4%), the improvement rate (83.8% vs 64.1%) and the clinical cure rate (78.9% vs 66.2%) of the treatment group were higher than the control group, with no serious adverse reactions [60]. This trial showed that LHQW could be considered to ameliorate clinical symptoms of COVID-19. Furthermore, 22 065 subjects were given HXZQ and Jinhao Jiye Granules (JHJR) for preventive administration for 5 consecutive days with the protection rate of the intervention group was 91.8%, which indicated that
they provided effective protection for the community [60]. Then, 123 COVID-19 patients were additionally given JHSG for 5 consecutive days [39], and the disappearance rate of fever symptoms in the treatment group was about 85.0%, which was 27.0% higher than that in the control group, and the Hamilton anxiety score decreased significantly in the treatment group (6.37) than in the control group (4.88), indicating that JHSG could effectively relieve the symptoms and anxiety of patients. A retrospective analysis of 68 patients found that the effective rate (91.2%) of the treatment group combined with the SFJD for 7 days was dramatically higher than that of the control group (70.6%, \( P < 0.05 \)), and no adverse events occurred [70]. The analysis revealed that the combined use of SFJD was effective and safe.

On the other hand, 214 confirmed cases in four pilot provinces were treated with QFJD (3 days as a course of treatment), which showed a total effective rate of more than 90% [72]. Among these, 98 patients were treated for 9 days and the total effective rate was 92.09%, of which the recovery rate was 41.13%, the significant efficiency was 26.92%, and the effective rate was 24.04% [71]. These trials provided strong evidence for the clinical application of QFJD. Furthermore, 80 patients were given MXSG for 5–7 days, the effective rate was 95% [34]; Forty patients were given MXSG combined with conventional treatment for 7 days, and the disappearance rates of the main clinical symptoms (fever, fatigue, cough) were 96.8% (30/31), 100.0% (28/28) and 81.8% (18/22) respectively [71]. It showed that the combined use of MXSG could effectively improve the symptoms of patients. And 44 patients were given XBJ treatment for 7 consecutive days, which indicated that the overall effectiveness of the intervention group (68.2%) was slightly higher than that of the control group (50.0%), and no serious adverse reactions occurred [78]. The clinical trials showed that XBJ also had a certain therapeutic effect. Nevertheless, there are dozens of TCM are conducting clinical trials at present, certain specific Chinese medicines are also incorporated (Table 3).

### Discussion and Summary

TCM has accumulated thousands of years’ experience in the treatment of pandemic and endemic diseases. Literature analysis has indicated the potential feasibility of QFJD, HSB-D, XBJ and other Chinese herbal preparations to treat COVID-19. Although its safety and effectiveness need to be clarified, it can provide a theoretical basis for subsequent experiments and clinical research. At present, most of the TCM preparations have been explored their potential mechanisms and targets by network pharmacology and molecular docking. The results showed that some TCM preparations could inhibit virus entry and replication in vivo by binding to Mpro and ACE2 targets, such as HXZQ, JHQG, LHQW, XBJ, TRQ and XYP. Also, they could play an anti-inflammatory role by acting on TNF, MAPK, Toll, NF-κB, IL-17, HIF-1 and other signaling pathways, which embodied the unique characteristics and advantages in the improvement of multiple organ damage. HSBD might act on the RIG-1/IRF/IFN-β, NF-κB/TNF-1L signaling pathways to reduce the release of inflammatory factors to alleviate lung injury. LHQW possibly modulated AGE/RAG1/ROS, PI3K/AKT and other signaling pathways to reduce kidney damage caused by inflammation. QFDP, MXSG potentially reduced the heart and brain damage linked with Caspase-3/Bcl-2, TNF-R1/MAPK and other signaling pathways. Compared with Western medicine treatment, TCM has its unique treatment concepts and principles. For example, QFDP is a common and core prescription in the prevention and treatment of COVID-19, and patients can be treated based on syndrome differentiation individually following the TCM theory [79]. Also, HXZQ could not only act on the main pathogenesis of “wet poison”, but also restore the qi mechanism to improve patients’ symptoms [70]. LHQW is a representative Chinese drug for treating viral infection-related diseases and has a broad clinical application basis [79]. XBJ showed no immunosuppressive effects in the treatment of clinical severe and critical COVID-19 patients. What’s more, the incidence of adverse reactions was low and the clinical effect was remarkable [76]. These findings have shown that compounds and preparations of TCM have their unique characteristics and potential advantages in treating COVID-19 (Fig. 1) and also provided a clinical basis for the follow-up TCM treatment plan and new drug development. Among them, the TCM composition and the action pathways for the prevention and treatment of the COVID-19 are shown in Table 1.

Moreover, literature mining and big data analysis showed that some natural products including quercetin, puerarin, porphyrin, quercetin-7-O-β-D-glucoside and patchouli alcohol in Patchouli have a better combination with Mpro, which could reduce virus replication. Seven effective compounds such as β-sitosterol and aloe-emodin in Rhubarb purportedly had the anti-viral, anti-inflammatory, anti-oxidative stress, anti-apoptosis and regulation of body immunity effects through multiple pathways and multiple targets. Meanwhile, the active ingredients of TCM such as glycyrrhizin and baicalin could inhibit the virus activity. For the experimental study of single Chinese herbs or extracts, Rhubarb, Scutellaria baicalensis Geor, Coptidis Rhizoma, Flos Lonicerae, Ficus isatidis and other antipyretics or antidotes have a certain therapeutic effect, which could provide a reference for the new combination of TCM. For example, there are some TCM sachets and sprays which have applied for patents to help reduce the prevalence and mortality. The effective components and action pathways of single TCM and natural active components for anti-SARS-CoV-2 are shown in Table 2.

The above summary suggests that TCM and its preparations showed the unique superiority of a full course of treatment and a full range of treatments. Early prevention and early treatment could reduce the mortality rate, improve symptoms, decrease the occurrence of complications and recurrence, which showed broad application prospects. The network pharmacological analysis indicates that the possible...
Fig. 1 Schematic diagram of possible action pathways of traditional Chinese medicine for prevention and treatment of COVID-19. 1 HXZQ; 2 JHQG; 3 LHQW; 4 XBJ; 5 TRQ; 6 QFPD; 7 SJS; 8 HSBD; 9 MXSG; 10 XCHT; 11 RDN; 12 XYP; 13 SFJD; 14 SMI; 15 YQFM

Table 1 Chinese herbal compound for anti-COVID-19

| Name                          | Composition                                                                 | Treatment approach                                                                 | References |
|-------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------|
| Huoxiang Zhengqi Oral Liquid (HXZQ) | Patchouli oil, Perilla leaf oil, Angelica dahurica, Atractylodes lancea, Magnolia officinalis (processing with Zingiber officinale), Born Pinellia ternate, Indian Bread, Tangerine peel, Areca Pericarpium, Licorice extract | Inhibit virus entry and replication; inhibit inflammation, and cytokine storm       | [26, 37]  |
| Jinhua Qinggan Granules (JHQG) | Flos Lonicerae, Gypsum Fibrosum, honey-prepared Herba Ephedrae, Armeniaca Semen Amarum, Scutellaria baicalensis Geor, Fructus Forsythiae, Fritillaria thunbergii, Anemarrhena asphodeloides, Arctium lappa, Artemisia annua, Herba Menthae, Radix Glycyrrhizae | Inhibit virus, regulate immunity, inflammation and apoptosis                        | [27, 38, 39] |
| Lianhua Qingwen Prescription (LHQW) | Fructus Forsythiae, Flos Lonicerae, Ephedra sinica, Armeniaca Semen Amarum, Gypsum Fibrosum, Isatidis indigotica, Dryopteris crassirhizoma, Houttuynia cordata, Pogostemon cablin, Rheum palmatum, Rhodiola rosea, Mentha haplocalyx, Radix Glycyrrhizae | Inhibit viral replication and reduce cytokine release from host cells; regulate immunity | [28]      |
| Shengjiang powder (SJS)        | Bombyx batryticat, Cryptotympana postulata ecdysis, Curcuma longa, Rheum palmatum | Intervene in virus invasion and suppress stress response                            | [40]      |
| Huashibaidu prescription(HSBD) | Raw ephedra, Armeniaca Semen Amarum, Gypsum Fibrosum, Radix Glycyrrhizae, Agastache rugosa, Magnoliae Officinalis Cortex, Atractylodes lancea, Amomum tsao-ko, Rhizoma Pinelliae Praeparata, Poria cocos, Rhus arbuc, Astragali radix, Draba nemorosa, Paeonia lactiflora | Inhibit inflammation, improve cytokine storm                                      | [41, 57]  |
| Qingfei Paidu Decoction(QFPD)  | Ephedrae Herba, Fried Glycyrrhiza uralensis, Armeniaca Semen Amarum, Gypsum Fibrosum, Cinnamomum cassia, Alismaorientalein, Polyoporus umbellatus, Atractylodes macrocephala, Poria cocos, Bupleuri Radix, Scutellaria baicalensis Geor, ginger-processed Pinelliaterna, Ginger, Astar tararicus, Farfarace Flos, Belamcandae Rhizoma, Asari Radix et Rhizoma, Dioscorea opposite Rhizoma, Aurantii Fructus Immaturus, Tangerine peel, Agastache rugosa | Inhibit virus invasion and replication; inhibit inflammation, improve cytokine stormy | [33, 42]  |
mechanisms of TCM were anti-virus, anti-inflammation, immune regulation, and organ protection through multiple components acting on multiple targets or pathways for the treatment of COVID-19. Different TCM may act on the same or similar targets or pathways. Nevertheless, the current understanding of the mechanisms of TCM is mainly produced from virtual simulation through molecular docking and network pharmacology analysis. To confirm these predicted mechan-

| Name                        | Composition                                                                                       | Treatment approach                                                                 | References |
|------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|------------|
| Maxing Shigan Decoction(MXSG) | Ephedra, Armeniacae Semen Amarum, Gypsum Fibrosum, Radix Glycyrrhizae                           | Inhibit inflammation; improve cytokine stormy and pulmonary interstitial edema       | [44]       |
| Xiaochaihu Tang(XCHT)        | Bupleuri Radix, Scutellaria baicalensis Geor, Pinellia ternate, Ginger, Ginseng Radix et Rhizoma, Radix Glycyrrhizae, Jujube | Inhibit inflammation;Reduce the temperature                                          | [45]       |
| Xuebijing injection(XBJ)     | Carthamus tinctorius, Radix Paconiae Rubra, Ligusticum chuanxiong Hort, Salvia miltiorrhiza, Angelica sinensis | Inhibit viral invasion and replication; inhibit inflammation                         | [29, 46, 47] |
| Reduning Injection(RDN)      | Artemisia annua, Flos Lonicerae, Gardeniae Fructus                                               | Inhibit inflammation                                                                | [47]       |
| Shengmai injection(SMI)      | Ginseng Radix et Rhizoma, Ophiopogonis Radix, Schisandra chinensis                              | Inhibit inflammation and oxidative stress; improve pulmonary fibrosis and microcirculation; regulate immune function | [58]       |
| Yiqi Fumai Lyophilized Injection(YQFM) | Red ginseng, Ophiopogonis Radix, Schisandra chinensis                                             | Inhibit inflammation and oxidative stress; improve pulmonary fibrosis and microcirculation; regulate immune function | [59]       |
| Tanreqing Injection(TRQ)     | Scutellaria baicalensis Geor, Bear Bile Powder, Caprae hircus cornu, Flos Lonicerae, Fructus Forsythiae | Inhibit inflammation;regulate immunity                                              | [30]       |
| Xiyanping Injection(XYP)     | Andrographis Herba                                                                                | Inhibit inflammation;regulate immunity                                              | [35]       |
| Shufeng Jiedu Capsules(SFJD)  | Polygonum cuspidatum, Fructus Forsythiae, Isatis indigotica, Bupleuri Radix, Herba Patrinae, Verbenae Herba, Rhizoma Phragmitis, Radix Glycyrrhizae | Inhibit inflammation and virus infection;                                          | [55, 56]  |
| Chinese medicine composition | Astachache rugosa, Chrysanthemi Indici Flos, Moslae Herba, Artemisia annua                        | Inhibit inflammation and virus infection;                                          | [49]       |
| Chinese medicine composition aromatherapy air disinfectant | Artemisia argy, Isatidis Radix, Folium Isatidis, Dryopteris crassirhizoma Nakai, Flos Lonicerae, Fructus Forsythiae, Scutellaria baicalensis Geor, Herba Menthae, Atractylodis Rhizoma, Aquilariae Lignum Resinatum, Viola yedoensis, Chrysanthemi Indici Flos, Houttuynia cordata | Sterilization, inhibit virus                                                   | [67]       |
| Chinese medicine composition sachet | Syzygium aromaticum, Platycladus orientalis, Angelica dahurica, Flos Lonicerae, Agastache rugosa, Eupatorium fortune, Cinnamomum cassia, Camphor, Saposnokivoxa divicata, Isatidis Radix, Artemisia argy, borneol | Inhibit bacterial and viral infection;                                              | [64]       |
| Chinese medicine atomizing agent | Qingai Oil, Artemisia annua oil, Ginseng oil, Astragalus oil, Rhodiola rosea, Grape seed oil | Inhibit virus; improve immunity;improve fatigue;                                   | [65]       |
| Chinese medicine fumigating bath preparation | Semiliquidambar Cathayesis, Cinnamomum camphora roots, Cymbopogon citratus, Scutellaria barbata, Polygonum Cuspidatum, Caulis Lonicerae, Fructus Forsythiae, Dandelion, Bupleuri Radix, Cynanchi Stauntonii, Armeniacae Semen Amarum, Aster tararicus, Rhizoma Phragmitis, Gaultheria yunnanensis | Promote metabolism and circulation;improve human immunity; inhibit virus           | [66]       |
| Fuzheng lung-saving medicine composition | Aconitum carmichaelii, Dried ginger, Honey-fried Licorice, Flos Lonicerae, Spina Gleditsiae, Ipomoea caurica, Pogostemon cablin, Tangerine peel | Inhibit inflammation and virus infection;Improve human body immunity                  | [63]       |
| Chinese medicine composition | Rhizoma, Scrophulariae Radix, Fructus Forsythiae, Cryptotympana pustulata ecdysis, Codonopsis pilosula, Herba Mentheae, Arctium lappa, Haematitatum | Inhibit virus; regulate immunity; reduce temperature;                                | [53]       |
isms, well designed in vitro cell experiments and in vivo animal studies based on these predictions are needed. Furthermore, many clinical studies and statistical methods still have deficiencies such as limited sample size and nonstandard trial methods etc. Therefore, the safety and effectiveness of TCM used in the treatment of emerging coronavirus infections should be carefully evaluated. The mechanism of action to improve COVID-19 remained not clear. It is worth to further evaluate its clinical efficacy for COVID-19, explore its potential molecular mechanism to improve multiple organ damage and identify their substance basis of the possible drug by multiple modern science and technology. Hopefully, the present study will provide reference and lay the foundation for the further development of new drugs for the prevention and treatment of COVID-19 and other viral infectious diseases.

References

[1] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin [J]. Nature, 2020, 579(7798): 270-273.
[2] Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission [J]. Sci China Life Sci, 2020, 63(3): 457-460.
[3] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020, 395(10223): 497-506.
[4] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China [J]. N Engl J Med, 2020, 382(18): 1708-1720.
[5] Chen R, Wang YG, Luo YP, et al. Preliminary exploration of Chinese medicine in treatment of novel coronavirus pneumonia [J]. J Hebei Tradit Chin Med Pharm, 2020, 35(2): 52-54.
[6] Wang YG, Qi WS, Ma JJ, et al. Clinical features and syndrome differentiation of novel coronavirus pneumonia in traditional Chinese medicine [J]. J Tradit Chin Med, 2020, 61(4): 281-285.
[7] Zhang L, Wang JJ, Lou ZJ, et al. Discussion on the characteristics of new coronavirus pneumonia treated with traditional Chinese medicine from the theory of the mechanism of Fuxie [J]. Tianjin J Tradit Chin Med, 2020, 37(1): 1-4.
[8] Zhang L, Yu J, Zhou Y, et al. Becoming a faithful defender: traditional Chinese medicine against coronavirus disease 2019 (COVID-19) [J]. Am J Chin Med, 2020, 48(1): 1-15.
[9] National Administration of Traditional Chinese medicine. Diagnosis and treatment protocol for COVID-19 (Trial Version 7) TCM protocol part [J]. Contin Med Educ, 2020, 34(4): 1-2.
[10] Pan F. Chinese medicine deeply intervenes in the whole pro-

### Table 2  Single traditional Chinese medicine and natural active ingredients for anti-COVID-19

| No. | Registration number | Scientific title                                                                 | Date of Registration |
|-----|--------------------|----------------------------------------------------------------------------------|----------------------|
| 1   | ChiCTR2000029434   | Capsule/Granule in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | 2020-02-01          |
| 2   | ChiCTR2000033133   | A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19) | 2020-05-21          |
| 3   | ChiCTR2000035633   | Clinical study of safety, tolerance, and pharmacokinetics of nebulizer (INF-K + anti-inflammatory factor TFF2) in healthy volunteers and exploration of PK/PD fitting modeling in clinical trials of Novel Coronavirus Pneumonia (COVID-19) patients | 2020-08-15          |
| 4   | ChiCTR2000032767   | A Medical Records Based Study for Clinical Efficacy and Safety of “clear lung detoxification soup” in the treatment of Novel Coronavirus Pneumonia (COVID-19) | 2020-05-09          |
| 5   | ChiCTR2000032205   | A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia | 2020-04-23          |
| 6   | ChiCTR2000030545   | Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial | 2020-03-16          |
| 7   | ChiCTR2000030388   | Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19) | 2020-03-01          |

**Table 3  The representative clinical trials of TCM for anti-COVID-19**
cess of diagnosis and treatment of new coronary pneumonia-interview with professor Zhang Boli, academician of Chinese Academy of Engineering and member of expert group of Central Steering Group [J]. China Med Her, 2020, 17(12): 1-3.

[11] Wang SX, Wang Y, Lu YB, et al. Diagnosis and treatment of novel coronavirus pneumonia based on the theory of tradition-al Chinese medicine [J]. J Integr Med, 2020, 18(4): 275-283.

[12] Li Y, Liu X, Guo L, et al. Traditional Chinese herbal medicine for treatment of COVID-19 (COVID-19) pneumonia: protocol for a systematic review and meta-analysis [J]. Syst Rev, 2020, 9(17): 75.

[13] Chen K, Chen H. Traditional Chinese medicine for combating COVID-19 [J]. Front Med, 2020, 14(5): 1-4.

[14] Wang W, Wang L, Jiang S, et al. Study on the medication rules in traditional Chinese medicine for prevention and treatment of novel coronavirus pneumonia based on ancient and modern medical cases cloud platform [J]. Beijing J Tradit Chin Med, 2020, 39(8): 805-901.

[15] Yang Y, Islam MS, Wang J, et al. Traditional Chinese medicine in the treatment of patients infected with 2019-nCoV disease (SARS-CoV-2): A review and perspective [J]. Int J Biol Sci, 2020, 16(10): 1708-1717.

[16] Shen AM, Zhang W, Wu Z, et al. TCN synthesis of Qingfei Paidu Decoction treating COVID-19 [J]. Liaoning J Tradit Chin Med, 2020, 47(3): 106-108.

[17] Zhao YS, Hou XS, Gao ZH, et al. Research on medication for severe type of COVID-19 based on Huashi Baidu prescription [J]. Chin Arch Tradit Chin Med, 2020, 38(6): 14-17.

[18] Tian Y, Li RM, Ren HW, et al. Feasibility of Shengmai Powder in convalescent patients with novel coronavirus pneumonia [J]. Drug Eval Res, 2020, 43(3): 378-383.

[19] Wan XM, Zhang YX, Li DK, et al. Feasibility of Yiqi Fumai Lyophilized Injection in treatment of novel coronary pneumonia (COVID-19) patients combined with cardiovascular disease [J]. Drug Eval Res, 2020, 43(3): 384-391.

[20] Li CY, Zhang XY, Liu S, et al. Current evidence and research prospects of Xuebijing Injection in treating novel coronavirus-infected pneumonia (COVID-19) [J]. Modern Tradit Chin Med Mater Med-Med World Sci Technol, 2020, 22(2): 242-247.

[21] Zhao D, Wu Y, Wang MH, et al. Discussion on using Huoxiang Zhengqi San in treating COVID-19 patients with digestive tract symptoms as first clinical manifestation [J]. Modern Tradit Chin Med Mater Med-Med World Sci Technol, 2020, 22(3): 1-4.

[22] Liu Y, Liu L, Cao MM, et al. Literature analysis of Chinese patent medicine treatment in the observation period of clinical management of coronavirus disease 2019 (trial 6th edition) [J]. Clin Med J, 2020, 18(2): 62-66.

[23] Yin YT, Wang JC, Jian RH, et al. Prevention of coronavirus disease 2019 with volatile oil of traditional Chinese medicine [J]. Negative, 2020, 11(04): 13-16-20.

[24] Yang L, Liu QJ, Bian Y, et al. Feasibility analysis of compounds glycyrrhizin in the treatment of COVID-19 [J]. West China J Pharm Sci, 2020, 35(3): 342-346.

[25] Sisay M. 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials [J]. Pharmacol Res, 2020, 156: 104779.

[26] Deng YJ, Liu BW, He ZX, et al. Study on active compounds from Huoxiang Zhengqi Oral Liquid for prevention of coronavirus disease 2019 (COVID-19) based on network pharmacology and molecular docking [J]. Chin Tradit Herb Drugs, 2020, 51(5): 1113-1122.

[27] Shen F, Fu ZY, Wu YR, et al. The potential molecular mechanism of active compounds binding SARS-CoV-2 specific target proteins in Huaqing Granules treat COVID-19 based on network pharmacology and high-throughput molecular docking fellowship [J]. Modern Tradit Chin Med Mater Med-World Sci Technol, 2020, 22(3): 622-631.

[28] Ling XY, Tao HL, Sun X, et al. Exploring material basis and mechanism of Lianhua Qingwen Prescription against coronavirus based on network pharmacology [J]. Chin Tradit Herb Drugs, 2020, 51(7): 1723-1730.

[29] He TM, Duan CC, Li XF, et al. Potential mechanism of Xuebijing Injection in treatment of coronavirus pneumonia based on network pharmacology and molecular docking [J]. Chin J Mod Appl Pharm, 2020, 37(4): 398-405.

[30] Kong Y, Wu HW, Chen Y, et al. Mechanism of Tanreqing Injection on treatment of coronavirus disease 2019 based on network pharmacology and molecular docking [J]. Chin Tradit Herb Drugs, 2020, 51(7): 1785-1794.

[31] Li Z, Yu KX. Exploration on mechanism of anti-coronavirus of Sophora flavescens through multi-pathway [J]. Chin Tradit Herb Drugs, 2020, 51(4): 888-894.

[32] Du HT, Wang P, Ma QY, et al. Preliminary study on the effective components and mechanism of Huoxiang Zhengqi Decoction in inhibiting the replication of novel coronavirus [J]. Modern Tradit Chin Med Mater Med-World Sci Technol, 2020, 22(3): 645-651.

[33] Peng XJ, Yang XJ, Xu G, et al. Investigating clinical efficacy and mechanism of Qingfei Paidu Decoction for treatment of COVID-19 based on integrative pharmacology [J]. Chin J Exp Tradit Chin Med Formulas, 2020, 26(16): 6-13.

[34] Shi X, Wei J, Liu MY, et al. Study on the overall regulation of Xuebijing Injection in treating COVID-19 [J]. Shanghai J Tradit Chin Med, 2020, 54(4): 46-52.

[35] Chen HS, Du QH. Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection[JOL]. 2020-03-10: www.preprints.org.

[36] Vaninov N. In the eye of the COVID-19 cytokine storm [J]. Nat Rev Immunol, 2020, 20(5): 277.

[37] Hao ZP, Liu YX, Hao L, et al. Research progress on potential application of Huoxiang Zhengqi in prevention and treatment of coronavirus disease 2019 [J]. Drug Clin, 2020, 35(3): 405-410.

[38] Lin JR, Zheng WW, Zen GX, et al. Study on the network pharmacology of Jinhua Qinggan Granules in the treatment of COVID-19 [J]. J Chin Med Mater, 2020, 8: 2074-2080.

[39] Mao Y, Su YX, Xue P, et al. Discussion on the mechanism of Jinhua Qinggan Granule in the treatment of novel coronavirus pneumonia [J]. J Chin Med Mater, 2020, 11: 2843-2849.

[40] Xu FB, Kuang YH, Xie K, et al. Study on the molecular mech-anism of Shengmai Powder anti-novel coronavirus based on structural similarity and molecular docking [J]. Chin J Med Mater, in press.

[41] Sun X, Tao JL, Xu SJ, et al. The molecular mechanism of treat-ing COVID-19 with Huashi Baidu Formula based on network pharmacology [J]. J Chin Med Mater, 2020, 8: 2050-2055.

[42] Gao H, Yao XS. Strengthen the research on the medicinal and edible substances to advance the development of the compre-hensive healthcare industry of TCMs [J]. Chin J Nat Med, 2019, 17(1): 1-2.

[43] Zhou MQ, Yang LP, Ma HJ, et al. Network pharmacological study of Qingfei Paidu Decoction intervening on cytokine storm mechanism of COVID-19 [J]. J Hainan Med Univ, 2020, 6(10): 721-729.

[44] Zhang Y, Yang H, He XH, et al. The curative mechanism of Maxingshigan Decoction on cytokine storm of COVID-19 pneumonia based on network pharmacology [J]. World Chin Med, 2020, 15(13): 1908-1913.

[45] Sun KB, Zhang YX, Liu J, et al. Network pharmacological ana-lysis and mechanism prediction of Xiaoaihu Decoction in treatment of COVID-19 with syndrome of pathogenic heat lingering in lung and obstructive cardinalate [J]. Chin Tradit Herb Drugs, 2020, 51(7): 1750-1760.

[46] Kong Y, Lin LL, Chen Y, et al. Mechanism of XueBijing Injec-tion on treatment of coronavirus disease 2019 based on net-work pharmacology [J]. Modern Tradit Chin Med Mater Med-World Sci Technol, 2020, 22(3): 552-560.
Sun XZ, Zhang YC, Liu XY, et al. Study on mechanism of Reduning Injection in treating novel coronavirus pneumonia based on network pharmacology [J]. J Chin Med Mater, 2020(07): 1797-1798.

Pan YZ, Wang HB, Zhang DD, et al. Chinese medicine composition with prevention and treatment of viral diseases and application thereof. CN111150755A [P]. 2020-05-15.

Chen L, Hu C, Hood M, et al. A novel combination of vitamin C, curcumin and glycyrrhizic acid potentially regulates immune and inflammatory response associated with coronavirus infections: A perspective from system biology analysis [J]. Nutrients, 2020, 12(4): 1193.

Wang T, Fu X, Chen Q, et al. Arachidonic acid metabolism and kidney inflammation [J]. Int J Mol Sci, 2019, 20(15): 3683.

Ren Y, Yao MC, Huo XQ, et al. Study on treatment of “cytokine storm ” by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway [J]. China J Chin Mater Med, 2020, 45(6): 1225-1231.

Wang L, Yang ZH, Zhang HR, et al. Study on the network pharmacology and preliminary evidence of Lianhua Qingwen in the treatment of novel coronavirus (2019-nCoV) pneumonia [J]. J Chin Med Mater, 2020(3): 772-778.

Lei M, Yang L. Chinese medicine composition and its application: China, CN111184805A [P]. 2020-05-22.

Li H, Lu CZ, Tang KC. Clinical observation on treatment of SARS with combination of Chaihuo Droplet Pill and Huoxiang Zhengqi Droplet Pill [J]. Chin J Integ Trad West Med, 2004, 24(4): 321-324.

Cao C, Cui Y, Chu YX, et al. Investigation on mechanism and active components of Shufeng Jiedu Capsule in treatment of COVID-19 based on network pharmacology and molecular docking [J]. Chin Tradit Herb Drugs, 2020, 51(9): 2283-2296.

Huang JW, An LF, Han X, et al. The potential mechanism of prevention and treatment of COVID-19 by Shufeng Jiedu Capsule was studied based on network pharmacology [J]. J Hainan Med Univ, 2020, 26(11): 814-819.

Xie YZ, Zhong CT, Ji SL, et al. Study of molecular mechanism of Huoshihuida Decoction on COVID-19 based on network pharmacology and molecular docking technology [J]. Pharmacol Clin Chin Mater Med, 2020, 36(3): 28-35.

Wang LF, Li HT, Wang Y, et al. Study on mechanism of Shengmai Injection against novel coronavirus pneumonia based on network pharmacology and molecular docking technology [J]. Chin Tradit Herb Drugs, 2020, 51(11): 2977-2987.

Han JY. The mechanisms underlying the beneficial effects of Ma-Xing-Shi-Gan-Tang on pulmonary interstitial edema and the beneficial effects of Yiqiufumai on shock [J]. Modern Tradit Chin Med Mater-World Sci Technol, 2020, 22(2): 248-256.

Zhou WJ, Zhang M, Yan YC, et al. The molecular mechanism of Pogostemonis Herba on the treatment of coronavirus pneumonia 2019 (COVID-19) based on network pharmacology and molecular docking [J]. J Pra Tradit Chin Int Med, 2020, 34(09): 1-4+120-122.

Xu LH, Huang XJ, Li YR, et al. Effect and potential mechanism of Rhubarb on COVID-19 based on the "Wenbingzaixia-qi-yu" theory [J]. Pharmacol Chin Clin Mater Med, 2020, 36(2): 85-90.

Zong Y, Yao WF, Ju WZ. To investigate the intervention ef-
fect of Chinese medicine monomer on cytokine storm induced by COVID-19 based on Interleukin-6 (IL-6) receptor [J]. Chin J Hosp Pharm, 2020, 40(11): 1182-1188.

Zhang ZD, Zou X. Fuzheng lung-saving medicine composition and application thereof. CN111110824A [P]. 2020-05-08.

Wang XC, Zhang DZ, Cheng SD. A sachet for effectively preventing new coronavirus pneumonia and influenza. CN111214689A [P]. 2020-06-02.

Li JF, Shi RH, Li JY. Anti-coronavirus Chinese medicine atomizer. CN111184799A [P]. 2020-05-22.

Yang HM, Chen CH, Chen TY, et al. A fumigating bathing preparation for preventing and controlling plague and its use method and application. CN111184823A [P]. 2020-05-22.

Song XB, Qin KQ, Chen FL, et al. Chinese medicine aromatherapy air disinfectant. CN111314480A [P]. 2020-05-12.

Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen Capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial [J]. Phytomedicine, 2020, 2020: 153242.

Yan BH, Jiang ZW, Zeng JP, et al. Large-scale prospective clinical study on prophylactic intervention of COVID-19 intervention in community population using Huoxiang Zhejiang Oral Liquid and Jinhao Jeer Granules [J]. Chin J Chin Mater Med, 2020, 45(13): 2993-3000.

Duan C, Xia WQ, Zheng CJ, et al. Clinical observation of Jinhua Qinggan Granules in treating new coronavirus-infected pneumonia[J]. J Tradit Chin Med, in press.

Cheng L, Liu F, Wu JH, et al. Clinical efficacy of Shufeng Jiedu Capsule combined with western medicine in treatment of common COVID-19 patients by retrospective analysis [J]. Chin J Exp Tradit Med Formulae, 2020, 26(16): 14-20.

Progress in screening research on effective prescriptions of traditional Chinese medicine-clinical observations in pilot provinces show that the total effective rate of Qingfei Paidu Decoction can reach more than 90%. J Tradit Chin Med, 2020, 19(1): 9.

Wang RQ, Yang SJ, Xie CG, et al. Clinical observation of Qingfesapu Decoction in the treatment of COVID-19 [J]. Pharmacol Clin Chin Mater Med, 2020, 36(1): 13-18.

Gong XY, Wei DR, Geng X, et al. Analysis on TCM clinical characteristics and syndromes of 80 patients with novel coronavirus pneumonia[J]. Chin J Inf Tradit Chin Med, in press.

Qu YF, Fang W, Jin YZ, et al. Forty cases of common COVID-19 treated with modified Ephedra and Apricot Kernel and Gypsum and Liquorice Decoction combined with western medicine routine treatment [J]. Henan Tradit Chin Med, 2020, 40(5): 666-669.

Zhang CY, Zhang S, Wang W, et al. Clinical observation of Xuebijing in the treatment of COVID-19 [J]. Chin J Hosp Pharm, 2020, 40(9): 964-967.

He QH, Liu YK, Sun XR, et al. The significance and role of “Qingfei Paidu Decoction ” recommended by the national health commission and the national administration of traditional Chinese medicine [J]. J Tradit Chin Med, 2020, 61(10): 829-832.

Tian XL, Hua C, Zhang Y, et al. Progress in the prevention and control of COVID-19 by Lianhua Qingwen [J]. J Liaoning Univ Tradit Chin Mater Med, 2020, 22(08): 184-187.

Cite this article as: DAI Yu-Jie, WAN Shi-Yao, GONG Shuai-Shuai, LIU Jin-Cheng, LI Fang, KOU Jun-Ping. Recent advances of traditional Chinese medicine on the prevention and treatment of COVID-19 [J]. Chin J Nat Med, 2020, 18(12): 881-889.